Christina Shafer - Marinus Pharmaceuticals Chief Officer
| MRNS Stock | USD 0.32 0.01 3.03% |
Executive
Christina Shafer is Chief Officer of Marinus Pharmaceuticals
| Age | 47 |
| Phone | 484 801 4670 |
| Web | https://marinuspharma.com |
Christina Shafer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christina Shafer against Marinus Pharmaceuticals stock is an integral part of due diligence when investing in Marinus Pharmaceuticals. Christina Shafer insider activity provides valuable insight into whether Marinus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Marinus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Marinus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christina Shafer over six months ago Disposition of 2385 shares by Christina Shafer of Marinus Pharmaceuticals at 9.52 subject to Rule 16b-3 | ||
Christina Shafer over six months ago Disposition of 2153 shares by Christina Shafer of Marinus Pharmaceuticals at 9.56 subject to Rule 16b-3 | ||
Christina Shafer over six months ago Sale by Christina Shafer of 2153 shares of Marinus Pharmaceuticals |
Marinus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5775) % which means that it has lost $0.5775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.8655) %, meaning that it created substantial loss on money invested by shareholders. Marinus Pharmaceuticals' management efficiency ratios could be used to measure how well Marinus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Moore | Edgewise Therapeutics | 60 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Francis Sarena | 89bio Inc | 53 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| CPA CPA | Viking Therapeutics | 53 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Shiva CPA | 89bio Inc | 58 | |
| Shiva Natarajan | 89bio Inc | 58 | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Tom Parry | Ovid Therapeutics | N/A | |
| Robert Ticktin | Pmv Pharmaceuticals | 62 | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Garret Bonney | Ovid Therapeutics | N/A | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 |
Marinus Pharmaceuticals Leadership Team
Elected by the shareholders, the Marinus Pharmaceuticals' board of directors comprises two types of representatives: Marinus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marinus. The board's role is to monitor Marinus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Marinus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marinus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, CFO Treasurer | ||
| Christina Shafer, Chief Officer | ||
| Joseph MD, Chief Officer | ||
| Thomas Lyons, Chief Officer | ||
| Sasha Ellis, VP Relations | ||
| Lisa Lejuwaan, VP Sales | ||
| Dayong Li, Senior Biometrics | ||
| Kimberly PharmD, Chief Officer | ||
| David Czekai, Manufacturing Chemistry | ||
| Molly Cameron, Director Relations | ||
| J Esq, General VP | ||
| Sonya Weigle, Human Relations | ||
| Scott MD, President CEO | ||
| Martha Manning, Gen VP | ||
| Alex Aimetti, Chief Officer | ||
| Mark Paternoster, Senior Development | ||
| PharmD PharmD, VP Assurance |
Marinus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Marinus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.74 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 83.03 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.